The medical aesthetics market is hot, and at the moment, much of that heat is coming from a tantalizing emerging market for the treatment of cellulite. Consumer demand is so great for cellulite treatments that a $3 billion cosmeceutical market has been created around lotions and massagers with minimal efficacy. To reach a potential blockbuster market--85% of women have cellulite--new device companies aim to demonstrate efficacy with the same discipline that they have brought to traditional therapeutic markets, hoping to create competitive and sustainable advantages.
by Mary Stuart
Caffeine scrubs, seaweed wraps, ceramic-coated neoprene shorts, and inflatable hip boots are only some of the whacky remedies that have...
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
Ultromics has secured $55m in Series C funding to advance its AI tool, EchoGo, which detects undiagnosed heart failure. The company's focus on diseases with available treatments resonated with investors.
Kevin Lobo, chairman and CEO of Stryker said that the company is not as exposed to China as others and has manufacturing operations in Europe, influencing the overall tariff impact.
At an Aug. 4 public meeting on MDUFA VI, FDA officials, industry representatives, and patient advocates outlined their priorities for the next user fee agreement, highlighting goals such as improved transparency, streamlined reviews, enhanced safety measures, and greater patient involvement.
